Cognition Therapeutics

Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of disease targets, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses and proprietary medicinal chemistry that insures novel, high quality small-molecule drug candidates.

Domain

cogrx.com

Employees

11-50

Last Funding

$30.0M

Founded

2006

Frequently Asked Questions

What technologies does Cognition Therapeutics use?+

Cognition Therapeutics uses 20 technologies including Astra, Elementor, Font Awesome.

What industry is Cognition Therapeutics in?+

Cognition Therapeutics operates in the Biotechnology industry.

Where is Cognition Therapeutics based?+

Cognition Therapeutics is headquartered in United States.

Need this data at scale?

Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.

Browse Datasets

Data last updated: June 2026